FORM 8-K

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                     Date of Report (Date of earliest event
                                   reported):

                               September 27, 2004

                            ULTRALIFE BATTERIES, INC.
             (Exact name of registrant as specified in its charter)

                                    Delaware
         (State or other jurisdiction of incorporation or organization)

                  0-202452                          16-132424013
                  --------                          ------------
          (Commission File Number)      (I.R.S. Employer Identification No.)
          ------------------------      ------------------------------------

                 2000 Technology Parkway, Newark, New York 14513
                 -----------------------------------------------
               (Address of principal executive offices) (Zip Code)

                                 (315) 332-24100
              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions.

[_]  Written  communications  pursuant to Rule 425 under the Securities Act (124
     CFR 240.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (124 CFR
     240.14a-12)

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (124 CFR 240.14d-2(b)

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (124 CFR 240.13e-4(c))



                                       1

Item 7.01. Regulation FD Disclosure. The Company announced that it has revised its financial outlook regarding its military business for the second half of 2004. Refer to the attached Exhibit 99.1 for the entire text of the release, which Exhibit is being furnished but not filed in accordance with Regulation FD. Item 9.01. Financial Statements, Pro Forma Financials and Exhibits. (a) Financial Statements of Business Acquired. Not applicable. (b) Pro Forma Financial Information. Not applicable. (c) Exhibits. 99.1 Press Release dated September 27, 2004 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ULTRALIFE BATTERIES, INC. Dated: September 27, 2004 By: /s/Robert W. Fishback --------------------- Robert W. Fishback Vice President - Finance & CFO 2

INDEX TO EXHIBITS (99) Additional Exhibits 99.1 Press Release dated September 27, 2004

                                                                    Exhibit 99.1

       Ultralife Batteries, Inc. Revises Outlook for Second Half Of 2004


    NEWARK, N.Y.--(BUSINESS WIRE)--Sept. 27, 2004--Ultralife
Batteries, Inc. (NASDAQ: ULBI) has revised its financial outlook
regarding its military business for the second half of 2004.
    With the end of its third fiscal quarter and in the absence of a
new order for BA-5390 batteries, the company has started to adjust its
production levels. Assuming the company does not receive additional
orders for its BA-5390 batteries during the remainder of the year,
management anticipates second half operating income and revenue could
be as low as $0.4 million and $42 million, respectively; as a result,
operating income and revenue for full year 2004 are expected to be no
less than $7.4 million and $97 million, respectively.
    This revised outlook also assumes that the company is not able to
receive a concession to the unit pricing on its current BA-5390
contract, which was based on significantly higher levels of
production. The company believes that it is contractually due a
revision in pricing because of the change in production schedules.
Should the military concur with the company's belief, the company
would recognize additional, as yet undetermined, revenue in the second
half of the year. Assuming no pricing concession is forthcoming by the
time the books for the third quarter are closed, management expects,
on a preliminary basis, third quarter operating income of
approximately $1.2 million and revenue of approximately $24 million.
    The company is working vigorously to address both the BA-5390
order visibility and the BA-5390 unit pricing. In the event that the
company receives an additional BA-5390 order or an adjustment to the
unit pricing, management will provide an updated outlook.
    In providing guidance for the second half of 2004 in the second
quarter earnings announcement, Ultralife indicated that uncertainties
existed in the order rate for the BA-5390 battery, arising from the
transfer of procurement authority from the U.S. Army Communications
and Electronics Command (CECOM) to the Defense Logistics Agency (DLA)
and the Next Gen II Phase IV award. The guidance assumed that the
military would place an order for additional BA-5390s during the third
quarter for production and delivery during the fourth quarter. Since
then, Ultralife has neither received additional orders for the BA-5390
batteries nor has the Next Gen II Phase IV award been announced. In
addition, because of lower than expected BA-5390 production run rates,
overhead absorption has declined, negatively impacting gross margin.
    "Unfortunately, although we have had ongoing communications with
the military during the quarter, the delay in announcing the Next Gen
II Phase IV contract award and the transfer of ordering responsibility
have made it difficult to predict BA-5390 orders for the remainder of
2004. These are extremely frustrating circumstances for us, but ones
that we have faced before and successfully overcome," said John
Kavazanjian, president and chief executive officer. "We also are on
familiar ground in discussing unit pricing on current contracts with
the military; for example, in the third quarter of 2003, we accepted
lower unit pricing from the military when costs came in lower than
assumptions in the initial contract award for one contract.
Operationally, we are preparing for the possibility that there is
indeed a hiatus in BA-5390 production, which may affect as many as 250
workers until production resumes."

    Kavazanjian concluded, "Our BA-5390 product provides higher
capacity, better safety and better value than the 30-year-old
technology that it is designed to replace, and we remain very
optimistic about its future demand. Notwithstanding the uncertain
military order flow for the rest of 2004, we are continuing to
vigorously advance our strategy of diversifying into target commercial
markets as illustrated by the growth of our rechargeable battery
business. We remain unwavering in our commitment to drive the company
toward the $200 million revenue level and beyond over the next three
to five years through continued growth in our military business,
including the successful award in the Next Gen II Phase IV
procurement, and through the principal engine of our growth, design
wins in commercial markets such as medical and automotive telematics."
    Management intends to provide an update of 2005 revenue and
operating income guidance in its third quarter earnings announcement
and conference call, scheduled to take place on October 28, when more
information is expected to be known about the Next Gen II Phase IV
award.

    About Ultralife Batteries, Inc.

    Ultralife is a leading developer, manufacturer, and marketer of
standard and customized lithium primary (non-rechargeable), lithium
ion and lithium polymer rechargeable batteries. Ultralife's
high-energy batteries use advanced lithium technology and are used in
military, industrial and consumer portable electronic products.
Through its range of standard products and ability to customize for a
wide range of applications, Ultralife is able to provide the next
generation of battery solutions. OEM, retail and government customers
include Energizer, Kidde Safety, Philips Medical Systems, Radio Shack
and the national defense agencies of the United States and United
Kingdom, among others.
    Ultralife's headquarters, principal manufacturing and research
facilities are in Newark, New York, near Rochester. Ultralife (UK)
Ltd., a second manufacturing and research facility, is located in
Abingdon, U.K. Both facilities are ISO-9001 certified.
    This press release contains forward-looking statements based on
current expectations that involve a number of risks and uncertainties.
The potential risks and uncertainties that could cause actual results
to differ materially include: loss of business with the U.S.
government, worsening global economic conditions, world events,
increased competitive environment and pricing pressures, disruptions
related to restructuring actions and delays. Further information on
these factors and other factors that could affect Ultralife's
financial results is included in Ultralife's Securities and Exchange
Commission (SEC) filings, including the latest Annual Report on Form
10-K.
    Detailed information on Ultralife is available at the Company's
web site, www.ultralifebatteries.com.

    Ultralife is a registered trademark of Ultralife Batteries, Inc.


    CONTACT: Ultralife Batteries, Inc.
             Robert W. Fishback, 315-332-7100
             bfishback@ulbi.com
                     or
             Investor Relations Contact:
             Lippert/Heilshorn & Associates, Inc.
             Jody Burfening, 212-838-3777
             jburfening@lhai.com
                     or
             Media Contact:
             Lippert/Heilshorn & Associates, Inc.
             Chenoa Taitt, 212-201-6635
             ctaitt@lhai.com